Figure 1.
![Kaplan–Meier curve of treatment persistence with subcutaneous [SC] infliximab [CT-P13] in patients switching from intravenous infliximab.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ecco-jcc/16/9/10.1093_ecco-jcc_jjac053/1/jjac053f0001.jpeg?Expires=1749503033&Signature=ijeSCC-T1fvaP5xu7sLSUQvrpL9mNk5a38RQctXVlWONmIANz81uKeH0j6mHq~t62WGC7JsBsFvo4dfBo8tWcQaM7YGTAsEjwwJUeal94nx-8HMM-4L9VQZimj4GMaAfYr6hh7deI0~W6iu5L~5qi-xkV-FtHBlnmB9vDpgiDNkAp68HBySEUq613eRtpLT4gHLrxYVlNV02CK~TLHI5NrOeUQ4cBFHTVrEeLoI4j3VB80OPJX2QEBARsnwKdpF08sEC9Fc-XMWg7xe3uOjD7wgypgcplryDn5BAKJ8is94TWUXlgVkeKimMeWs40NByNKXfY53qR6Nm5pKSwTRPQw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan–Meier curve of treatment persistence with subcutaneous [SC] infliximab [CT-P13] in patients switching from intravenous infliximab.
Kaplan–Meier curve of treatment persistence with subcutaneous [SC] infliximab [CT-P13] in patients switching from intravenous infliximab.
